Use Effectiveness of Medical Devices: A Case Study on the Deployment of Ultrasonographic Devices

Background: In the sense of Act No. 123/2000 Coll., as amended (hereinafter referred to as “the Act”), a medical device is understood to be a wide range of resources, especially medical equipment. To implement innovative technologies in practice, it is becoming extremely important to be cost-conscious and effective. The aim of the article is to use an ultrasonographic device case study in a selected hospital to show the possibility of solving the use effectiveness of medical devices. Methods: Within the first step, a summary of the use of ultrasonographic devices is developed in terms of performance number and time. Also, a summary of all costs for the last 5 years has been created. The analyzed ultrasonographic device set is evaluated in terms of activity indicators, profitability, and Du Pont decomposition. Revenues from the operation of individual instruments and payroll productivity are taken into account. All of this is evaluated in the context of the requirements of the department and the spectrum of ultrasonographic devices. Results: The results show that the economic evaluation of device use efficiency, comparing the requirements of the department and spectrum of the devices, suggests a major revision in use of these devices and savings. Conclusion: The new design of the most profitable system differs significantly in the arrangement of individual ultrasonographic devices. The benefit of the study is not just a newly designed organization-specific arrangement, but it can be perceived as a modeling approach that can be used to analyze other sets of medical technology.

[1]  Laura Vallejo-Torres,et al.  Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach , 2008, International Journal of Technology Assessment in Health Care.

[2]  Marek Penhaker,et al.  The potential of medical device industry in technological and economical context , 2015, Therapeutics and clinical risk management.

[3]  M. Dijkgraaf,et al.  Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease , 2014, Orphanet Journal of Rare Diseases.

[4]  Jacky Akoka,et al.  An expert system for feasibility assessment of product development , 1994 .

[5]  Maarten J. IJzerman,et al.  Group Decision Making with the Analytic Hierarchy Process in Benefit-Risk Assessment: A Tutorial , 2014, The Patient - Patient-Centered Outcomes Research.

[6]  Jianqian Chao,et al.  Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B , 2016, PloS one.

[7]  P. Marešová,et al.  Legislative and ethical aspects of introducing new technologies in medical care for senior citizens in developed countries , 2016, Clinical interventions in aging.

[8]  Ming-Chyuan Lin,et al.  Using AHP and TOPSIS approaches in customer-driven product design process , 2008, Comput. Ind..

[9]  İhsan Kaya,et al.  Investment project evaluation by a decision making methodology based on type-2 fuzzy sets , 2015, Appl. Soft Comput..

[10]  Hywel C. Williams,et al.  Better Decision Making for Evaluating New Medical Device Projects: A Real Options Approach: , 2008 .

[11]  A. Stern,et al.  Limits on use of health economic assessments for rare diseases. , 2014, QJM : monthly journal of the Association of Physicians.

[12]  M. Dijkgraaf,et al.  Cost-effectiveness of enzyme replacement therapy for Fabry disease , 2012, Orphanet Journal of Rare Diseases.

[13]  Blanka Klímová,et al.  Legislative aspects of the development of medical devices. , 2015, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti.